Clinical Trial Update: A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

AK117, an anti-CD47 antibody developed by Akeso, is being evaluated in adults with acute myeloid leukemia in a Phase 1/2 trial. The study status is active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AK117 (AK117)

Snippet

Sponsor: Akeso | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING